FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC

ODAC votes that olaparib-abiraterone combination should be restricted to <em>BRCA</em>-positive subset

Related Keywords

California ,United States ,North Carolina ,Columbia University ,New York ,Colorado ,Massachusetts ,Mike Bassett ,Chana Weinstock ,Daniel George ,Los Angeles ,Richard Pazdur ,Neil Vasan ,Jorge Nieva ,Astrazeneca Laurence Toms ,Duke Cancer Institute In Durham ,Columbia University Medical Center ,Oncology Center ,Office Of Oncologic Diseases ,University Of Colorado Cancer Center ,Astrazeneca ,Oncologic Drugs Advisory Committee ,Christopher Lieu ,Colorado Cancer Center ,New York City ,Oncologic Diseases ,Southern California ,Keck School ,Laurence Toms ,Duke Cancer Institute ,